Cancer Immunology Research
Cell Reports Medicine
American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) San Francisco, CA February 16-18, 2023.
Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Frontiers in Immunology publication, Saura-Esteller, et al.
European Hematological Association (EHA) 2022 Congress presentation Broijl, et al.
2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation
Brojil, et al.
Roeland Lameris, Jurjen M Ruben, Iris de Weerdt, Rob Roovers, Arnon P Kater, Thilo Riedl, Victoria Iglesias, Benjamin Winograd, Ton EP Adang, Tanja D de Gruijl, Paul WHI Parren, Hans J van der Vliet
Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity that is of particular concern in the elderly CLL population. Vγ9Vδ2-T cells form a conserved T-cell subset with strong intrinsic immunotherapeutic potential, largely because of their capacity to be triggered by phosphoantigens that can be overproduced by CLL and other malignant cells. Specific activation of Vγ9Vδ2-T cells by a bispecific antibody may improve the efficacy and toxicity of autologous T-cell–based therapy in CLL. Link to full article